Global Clot Busting Drugs Market Growth, Expected to Surpass USD 58.4 Billion by 2032 at a 7.3% of CAGR

Global Clot-Busting Drugs Market
Global Clot-Busting Drugs Market

The global clot-busting drugs market is expected to have a significant increase in market value, reaching approximately USD 28.8 billion in 2022. By the end of 2032, the market is expected to have grown at a solid Compound Annual Growth Rate (CAGR) of 7.3%, propelling it to a valuation of USD 58.4 billion.

Among other thrombotic diseases, thrombolytics—drugs that break up blood clots—are crucial for the treatment of heart attacks, strokes, and pulmonary emboli. These drugs can improve patient outcomes and lower the risk that severe consequences in critical medical conditions will occur by dissolving blood clots and restoring blood flow to injured tissues.

Companies are creating new clot busting medications with fewer side effects and at a lower cost because customers aren’t receiving clot busting medicines as intended because of misconceptions and the treatments’ negative consequences. It is anticipated that this will greatly increase the acceptance and use of clot-busting drugs. Over the anticipated timeframe, increasing product releases and approvals are anticipated to fuel more market expansion.

Gain a Competitive Edge: Request Your Sample:

Key Takeaways from Market Study

  • Anticoagulants are the leading segment as a product, and hold approximately 36.7% market share in 2021, due to the rise in chronic diseases, the development of anticoagulant medicines has become more molecularly and biologically advanced, and emerging nations are increasingly using novel oral anticoagulants.
  • Pulmonary Embolism are the leading segment by indication, and held about 31.2% market share in 2021, owing to the increasing number of cancer patients and patients who have a family history of cardiovascular issues.
  • Injectable category is the leading segment in route of administration of drugs by holding more than half of the global market share owed to growing need for tools like safety syringes, prefilled syringes, and auto-injectors for the prevention of needle stick injuries.
  • Hospital Pharmacy is the leading distribution channel as of 2021, withholding about one third of the global market share by value due to wide range of product availability, convenience and patients’ reliance on hospitals for treatments.
  • By region, North America is leading in the global clot busting drugs market with 32.4% of the revenue share on 2021 and is expected to continue to do so with a projected CAGR rate of 8.0% during the forecasted years.

“Rising initiatives to promote health benefits of clot busting drugs, as well as the increasing awareness about the prevention of heart attacks and strokes is set to propel the sales of clot busting drugs devices across the globe,” says an analyst of Future Market Insights.

Market Competition

The market for clot busting drugs is quite competitive due to the presence of numerous local or regional players. The companies are concentrating on implementing different business strategies, such as product launches, drug development, and geographic expansions. For Instance:

  • In Dec 2021, Janssen Pharmaceutical received U.S. FDA approval for its oral anticoagulant called XARELTO (rivaroxaban). The drug was approved for 2 indications for pediatric category which includes prophylaxis of DVT or deep vein thrombosis resulting in pulmonary embolism.
  • AstraZeneca’s Brilinta (ticagrelor) received FDA approval for its P2Y12 receptor antagonist, an oral, reversible drug that prevents platelet activation, in June 2020 to lower the risk of a stroke or a first heart attack in patients with high-risk of coronary artery disease (CAD).

Customization Available:

Key Segments Covered in Clot Busting Drugs Industry Research

By Product:

  • Thrombolytic Drugs
  • Anti-Platelet Drugs
  • Anticoagulants
  • Others

By Indication:

  • Pulmonary Embolism
  • Deep Vein Thrombosis
  • Atrial Fibrillation
  • Others

By Route of Administration:

  • Oral
  • Injectable

By Distribution Channel:

  • Hospital Pharmacy
  • Drug Store
  • Online Pharmacy
  • Retail Pharmacy

By Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle-East and Africa (MEA)

Explore In-Depth Market Insights: Purchase Now to Access:

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705

For Sales Enquiries:
LinkedInTwitterBlogs | YouTube

Leave a comment

Your email address will not be published. Required fields are marked *